Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
When doing the right thing is the best thing, Part 2 DURBAN, South Africa – In another example of what happens when proven HIV interventions are […]
While tuberculosis remains the number one killer of people living with HIV – with one in three HIV-related deaths attributable to tuberculosis – the burden to […]
From a human-scented mosquito trap to rapid diagnostics, USAID funds research and development against Zika
Agency picks 21 of 900 ideas from around the world A research center in Tanzania will develop inexpensive sandals treated to ward off mosquito bites. Investigators […]
When the first children with fevers and swollen neck glands arrived at public health clinics in the Nyimba District of Zambia in March 2015, health workers […]